Anifrolumab

證據等級: L5

預測適應症: 0 個

Anifrolumab: From Systemic Lupus Erythematosus to — (No TxGNN Prediction Data in This Evidence Pack)

One-Sentence Summary

Anifrolumab (SAPHNELO) is a fully human monoclonal antibody targeting the type I interferon receptor (IFNAR1), approved for moderate-to-severe systemic lupus erythematosus (SLE) in adults. This Evidence Pack contains no TxGNN-predicted new indications, and two critical data gaps — missing package insert safety information (Blocking) and missing mechanism of action data (High) — prevent a complete repurposing assessment. No repurposing recommendation can be issued until these gaps are remediated and the prediction pipeline is re-run.

Quick Overview

Item	Content
Original Indication	Moderate-to-severe systemic lupus erythematosus (SLE)
Predicted New Indication	No predictions available in this Evidence Pack
TxGNN Prediction Score	N/A
Evidence Level	N/A
Malaysia Market Status	✓ Marketed
Number of Registrations	1
Recommended Decision	Hold

Why No Prediction Is Reasonable to Evaluate

The predicted_indications field in this Evidence Pack is empty. Three likely causes:

Pipeline not yet executed — The TxGNN prediction run for DB11976 may not have been triggered or completed.
DrugBank ID mapping failure — If ANIFROLUMAB was not successfully matched to a node in the knowledge graph, no candidate diseases would be scored.
Data staging issue — Prediction outputs may exist upstream but were not merged into this v4 Evidence Pack.

In parallel, two data gaps block evaluation even if predictions were available:

Gap ID	Item	Severity	Impact
DG001	Package insert warnings & contraindications	Blocking	Cannot complete S1 safety pre-screen
DG002	Mechanism of action (MOA)	High	Cannot perform mechanistic rationale scoring

Drug Background: Known Mechanism of Action

Although the MOA field is marked as a data gap in this Evidence Pack, anifrolumab’s mechanism is well characterised in the published literature and the DrugBank record for DB11976.

Anifrolumab is a fully human IgG1κ monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1), blocking signalling from all type I interferons (IFN-α, IFN-β, IFN-ω, and related subtypes). Type I IFN signalling is pathologically overactivated in approximately 60–80% of SLE patients, driving inflammatory cytokine production, dendritic cell activation, and B-cell autoreactivity. By occupying IFNAR1, anifrolumab suppresses the interferon gene signature (IFNGS) and attenuates downstream JAK1/TYK2-mediated transcription of pro-inflammatory genes.

This mechanism is not SLE-exclusive. Other conditions characterised by elevated type I IFN activity — including dermatomyositis, primary Sjögren’s syndrome, systemic sclerosis, and ANCA-associated vasculitis — are biologically plausible targets. However, none are confirmed via TxGNN prediction in this data pack, and this background information is provided solely for context pending re-run of the prediction pipeline.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not populated)	Anifrolumab — SAPHNELO	(Not populated)	Moderate-to-severe active SLE in adults (details not yet extracted into this Evidence Pack)

Note: The Evidence Pack records 1 registered licence with market status “已上市” (Marketed), but all licence detail fields — including licence number, product name, dosage form, manufacturer, and approved indication text — are unpopulated. Please verify directly against the NPRA online registry or retrieve the full licence record before proceeding.

Safety Considerations

Please refer to the package insert for safety information.

Data Gap Alert (DG001 — Blocking): Both the key warnings and contraindications fields are listed as [Data Gap] in this Evidence Pack. A formal safety assessment cannot be completed. Based on the drug class (anti-IFNAR1 biologic), clinicians should be aware that typical considerations for this category include: serious and opportunistic infections (including influenza and herpes zoster), live attenuated vaccine contraindication during treatment, infusion-related and hypersensitivity reactions, and potential immunosuppression in combination with other biologics. These are general class considerations only and must be confirmed against the approved Malaysian package insert before any clinical decision.

Conclusion and Next Steps

Decision: Hold

Rationale: This Evidence Pack is materially incomplete — no TxGNN repurposing predictions are present, critical safety data is absent at a blocking severity level, and licence detail fields are unpopulated. Issuing a repurposing recommendation under these conditions would not be scientifically defensible.

To proceed, the following is needed:

[Blocking — DG001] Download and parse the NPRA/TFDA package insert PDF for SAPHNELO (anifrolumab) to extract approved warnings, contraindications, special population guidance, and handling requirements; populate the safety.key_warnings and safety.contraindications fields
[High — DG002] Query DrugBank API for DB11976 to retrieve the full MOA text and populate the drug.original_moa field
[Pipeline] Re-run the TxGNN KG + DL prediction pipeline with confirmed DrugBank ID DB11976 to populate predicted_indications
[Regulatory] Retrieve complete licence detail record from NPRA (licence number, product name, dosage form, approved indication text) and populate taiwan_regulatory.licenses[0]
[Re-evaluation] Once all four items above are resolved, resubmit the Evidence Pack (target v5) for a full L1–L5 evidence-level repurposing assessment
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.